[1]杨慧孟,娄　阁.一氧化氮供体治疗骨质疏松症研究进展[J].新乡医学院学报,2016,33(6):548-551.[doi:10.7683/xxyxyxb.2016.06.029]
　YANG Huimeng,LOU Ge.Research progress of nitric oxide donor in the treatment of osteoporosis[J].Journal of Xinxiang Medical University,2016,33(6):548-551.[doi:10.7683/xxyxyxb.2016.06.029]
点击复制

一氧化氮供体治疗骨质疏松症研究进展
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
33
期数:
2016年6
页码:
548-551
栏目:
综述
出版日期:
2016-06-05

文章信息/Info

Title:
Research progress of nitric oxide donor in the treatment of osteoporosis
作者:
杨慧孟; 娄　阁
（哈尔滨医科大学附属第三医院妇科，黑龙江　哈尔滨　150081）
Author(s):
YANG Huimeng; LOU Ge
关键词:
骨质疏松症; 一氧化氮供体; 药物治疗
分类号:
R681
DOI:
10.7683/xxyxyxb.2016.06.029
文献标志码:
A
摘要:
骨质疏松症是一种骨重塑增加的疾病，骨吸收与骨形成不平衡，且骨吸收大于骨形成，导致骨密度降低及骨微结构破坏。目前，骨质疏松症的治疗存在明显缺陷，需要研究新的抗骨质疏松药物。研究发现，雌激素对骨的一些效应是由一氧化氮（NO）介导的，NO供体是治疗骨质疏松症的一种新策略。本文对NO供体治疗骨质疏松症的研究进展进行综述。

参考文献/References:

［1］　MPALARIS V，ANAGNOSTIS P，GOULIS D G，et al.Complex association between body weight and fracture risk in postmenopausal women［J］.Obesity Rev，2015，16（3）：225-233.
［2］　METGE C J，LESLIE W D，MANNESS L J，et al.Postfracture care for older women：gaps between optimal care and actual care［J］.Can Fam Physician，2008，54（9）：1270-1276.
［3］　CARRADORI S，MOLLICA A，DE MONTE C，et al.Nitric oxide donors and selective carbonic anhydrase inhibitors：a dual pharmacological approach for the treatment of glaucoma，cancer and osteoporosis［J］.Molecules，2015，20（4）：5667-5679.
［4］　JOHNELL O，KANIS J A.An estimate of the worldwide prevalence and disability associated with osteoporotic fractures［J］.Osteoporos Int，2006，17（12）：1726-1733.
［5］　GULLBER B，JOHNELL O，KANIS J A.World-wide projections for hip fracture［J］.Osteoporos Int，1997，7（5）：407-413.
［6］　IAMAL S A，HAMILTON C J.Nitric oxide donors for the treatment of osteoporosis［J］.Curr Osteoporos Rep，2012，10（1）：86-92.
［7］　SATTERWITHE J，HEATHMAN M，MILLER P D，et al.Pharmacokinetics of teriparatide［rhPTH（1-34）］ and calcium pharmacodynamics in postmenopausalwomen with osteoporosis［J］.Calcif Tissue Int，2010，87（6）：485-492.
［8］　VAHLE J L，LONG G G，SANDUSKY G，et al.Bone neoplasms in F344 rats given teriparatide［rhPTH（1-34）］ are dependent on duration of treatment and dose［J］.Toxicol Pathol，2004，32（4）：426-438.
［9］　MILLER P D.Safety of parathyroid hormone for the treatment of osteoporosis［J］.Curr Osteoporos Rep，2008，6（1）：12-16.
［10］　MAJUMDAR S R，MCALISTER F A，JOHNSON J A，et al.Critical impact of patient knowledge and bone density testing on starting osteoporosis treatment after fragility fracture：secondary analyses from two controlled trials［J］.Osteoporos Int，2014，25（9）：2173-2179.
［11］　EVANS D M，RALSTON S H.Nitric oxide and bone［J］.J Bone Miner Res，1996，11（3）：300-305.
［12］　CHAE H J，PARK R K，CHUNG H T，et al.Nitric oxide is a regulator of bone remodelling［J］.J Pharm Pharmacol，1997，49（9）：897-902.
［13］　PALMER R M，FERRIGE A G，MONCADA S.Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor［J］.Nature，1987，327（6122）：524-526.
［14］　GHASEMI M，NEMATBAKHSH M，DANESHMAND F A，et al.Role of nitric oxide in kidney and liver（as distance organ） function in bilateral renal ischemia-reperfusion：effect of L-arginine and NG-nitro-L-arginine methyl ester［J］.Adv Biomed Res，2015，4：233.
［15］　HSU Y C，LEE P H，LEI C C，et al.Nitric oxide donors rescue diabetic nephropathy through oxidative-stress-and nitrosative-stress-mediated Wnt signaling pathways［J］.J Diabetes Investig，2015，6（1）：24-34.
［16］　ROGERS N E，IGNARRO L J.Constitutive nitric oxide synthase from cerebellum is reversibly inhibited by nitric oxide formed from arginine［J］.Biochem Biophys Res Commun，1992，189（1）：242-249.
［17］　LIPTON S A，CHOI Y B，PAN Z H，et al.A redox based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso compounds［J］.Nature，1993，364（6438）：626-632.
［18］　WINDHAUSEN T，SQUIFFLET S，RENN J，et al.BMP Signaling regulates bone morphogenesis in zebrafish through promoting osteoblast function as assessed by their nitric oxide production［J］.Molecules，2015，20（5）：7586-7601.
［19］　KOHGAMI S，OGATA T，MORINO T，et al.Pharmacological shift of the ambiguous nitric oxide action from neurotoxicity to cyclic GMP-mediated protection［J］.Neurol Res，2010，32（9）：938-944.
［20］　MANCINI L，MORADI-BIDHENDI N，BECHERINI L，et al.The biphasic effects of nitric oxide in primary rat osteoblasts are cGMP dependent［J］.Biochem Biophys Res Commun，2000，274（2）：477-481.
［21］　RALSTON S H，HO L P，HELFRICH M H，et al.Nitric oxide：a cytokine-induced regulator of bone resorption［J］.J Bone Miner Res，1995，10（7）：1040-1049.
［22］　BRANDI M L，HUKKANEN M，UMEDA T，et al.Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms［J］.Proc Natl Acad Sci USA，1995，92（7）：2954-2958.
［23］　ARMOUR K E，VAT′T HOF R J，GRABOWSKI P S，et al.Evidence for a pathogenic role of nitric oxide in inflammation induced osteoporosis［J］.J Bone Miner Res，1999，14（12）：2137-2142.
［24］　VAN′T HOF R J，ARMOUR K J，SMITH L M，et al.Requirement of the inducible nitric oxide synthase pathway for IL-1-induced osteoclastic bone resorption［J］.Proc Natl Acad Sci USA，2000，97（14）：7993-7998.
［25］　VAN′T HOF R J，RALSTON S H.Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity［J］.J Bone Miner Res，1997，12（11）：1797-1804.
［26］　PERCIVAL M D，OUELLET M，CAMPAGNOLO C，et al.Inhibition of cathepsin K by nitric oxide donors：evidence for the formation of mixed disulfides and a sulfenic acid［J］.Biochemistry，1999，38（41）：13574-13583.
［27］　RIANCHO J A，SALAS E，ZARRABEITIA M T，et al.Expression and functional role of nitric oxide synthase in osteoblast-like cells［J］.J Bone Miner Res，1995，10（3）：439-446.
［28］　MANCINI L，MORADI-BIDHENDI N，BECHERINI L，et al.The biphasic effects of nitric oxide in primary rat osteoblasts are cGMP dependent［J］.Biochem Biophys Res Commun，2000，274（2）：477-481.
［29］　JOSHUA J，KALYANARAMAN H，MARATHE N，et al.Nitric oxide?As a mediator of estrogen effects in osteocytes［J］.Vitam Horm，2014，96：247-263.
［30］　RALSTON S H，TODD D，HELFRICH M H，et al.Human osteoblast-like cells produce nitric oxide and expressinducible nitric oxide synthase［J］.Endocrinology，1994，135（1）：330-336.
［31］　MACPHERSON H，NOBLE B S，RALSTON S H.Expression and functional role of nitric oxide synthase isoforms in human osteoblast-like cells［J］.Bone，1999，24（3）：179-185.
［32］　ARMOUR K E，ARMOUR K J，GALLAGHER M E，et al.Defective bone formation and anabolic responses to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide sythase［J］.Endocrinology，2001，142（2）：760-766.
［33］　SUH K S，RHEE S Y，KIM Y S，et al.Protective effect of liquiritigenin against methylglyoxal cytotoxicity in osteoblastic MC3T3-E1 cells［J］.Food Funct，2014，5（7）：1432-1440.
［34］　NEVZATI E，SHAFIGHI M，BAKHTIAN K D，et al.Estrogen induces nitric oxide production via nitric oxide synthase activation in endothelial cells［J］.Acta Neurochir Suppl，2015，120：141-145.
［35］　AILHAUD G，MICHIELS J F，HEYMANN D，et al.Oxytocin reverses ovariectomy-induced osteopenia and body fat gain［J］.Endocrinology，2014，155（4）：1340-1352.
［36］　RUSSELL K S，HAYNES M P，SINHA D，et al.Human vascular endothelial cells contain membrane binding sites for estradiol，which mediate rapid intracellular signaling［J］.Proc Natl Acad Sci USA，2000，97（11）：5930-5935.
［37］　MENDELSOHN M E，KARAS R H.Rapid progress for non-nuclear estrogen receptor signaling［J］.J Clin Invest，2010，120（7）：2277-2279.
［38］　GRASSI F，FAN X，RAHNNERT J，et al.Bone remodeling is moredynamic in the endothelial nitric oxide synthase mouse［J］.Endocrinology，2006，147（9）：4392-4399.
［39］　WIMALAWANSA S J，DE MARCO G，GANGULA P，et al.Nitric oxide donor alleviates ovariectomy-induced bone loss［J］.Bone，1996，18（4）：301-304.
［40］　HUKKANEN M，PLATTS L A，LAWES T，et al.Effect of nitric oxide donor nitroglycerin on bone mineral density in a rat model of estrogen deficiency-induced osteopenia［J］.Bone，2003，32（2）：142-149.
［41］　REJNMARK L，VESTERGAARD P，MOSEKILDE L.Decreased fracture risk in users of organic nitrates：a nationwide case-control study［J］.J Bone Miner Res，2006，21（11）：1811-1817.
［42］　JAMAL S A，HAMILTON C J，EASTELL R，et al.Effect of nitroglycerin ointment on bone density and strength in postmenopausal women：a randomized trial［J］.JAMA，2011，305（8）：800-807.
［43］　MARATHE N，RANGASWAMI H，ZHUANG S，et al.Prosurvival effects of 17β-estradiol on osteocytes are mediated by nitric oxide/cGMP via differential actions of cGMP-dependent protein kinases Ⅰ and Ⅱ［J］.J Biol Chem，2012，287（2）：978-988.
［44］　RANGASWAMI H，SCHWAPPACHER R，MARATHE N，et al.Cyclic GMP and protein kinase G control a Src-containing mechanosome in osteoblasts［J］.Sci Signal，2010，3（153）：ra91.
［45］　MANCINI L，MORADI-BIDHENDI N，BECHERINI L，et al.The biphasic effects of nitric oxide in primary rat osteoblasts are cGMP dependent［J］.Biochem Biophys Res Commun，2000，274（2）：477，481.
［46］　HAGIWARA H，INOUE A，YAMAGUCHI A，et al.cGMP produced in response to ANP and CNP regulates proliferation and differentiation of osteoblastic cells［J］.Am J Physiol，1996，270（5 Pt 1）：C1311-C1318.
［47］　WIMALAWANSA S J，GRIMES J P，WILSON A C，et al.Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss［J］.J Clin Endocrinol Metab，2009，94（9）：3356-3364.

相似文献/References:

[1]田玉慧,崔艳燕,杨献军,等.麦胚提取物对大鼠成骨细胞增殖分化和矿化的影响[J].新乡医学院学报,2002,19(04):242.

更新日期/Last Update: 2016-06-05